(AMBEA) Ambea - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0009663826
AMBEA: Care, Nursing, Homes, Schools, Rehabilitation, Services
Ambea AB (publ) stands as a cornerstone in the Nordic care sector, delivering elderly care, disability care, and psychosocial support primarily across Sweden, Norway, and Denmark. Established in 1993 and headquartered in Solna, Sweden, the company has cultivated a diversified portfolio that addresses a spectrum of care needs, making it a resilient investment opportunity.
Ambeas operational structure is segmented into five distinct brands, each tailored to specific care niches. Nytida specializes in social care services and schools for children and young people with neuropsychiatric disorders, addressing a critical and specialized need. Vardaga and Altiden focus on elderly care, offering nursing homes and home care services, capitalizing on the growing demographic of aging populations. Stendi provides a broad range of services, including personal assistance and residential care, ensuring versatility in meeting diverse client needs. Klara complements these services with staffing solutions and ambulatory care teams, crucial for maintaining high service quality and efficiency.
Beyond direct care, Ambeas Lära brand underscores its commitment to excellence through skills development and coaching programs. These programs ensure that staff are well-trained, enhancing service quality and ensuring compliance with regulatory standards, which is vital for sustained operational excellence and trust.
From a financial perspective, Ambea presents a compelling profile. With a market capitalization of approximately 7,806.84M SEK, the company demonstrates moderate valuation with a P/E ratio of 13.47. The P/B ratio of 1.64 indicates a market valuation exceeding book value, likely reflecting intangible assets such as brand reputation and operational expertise. The P/S ratio of 0.56 suggests a favorable value proposition, appealing to investors seeking growth in the healthcare sector driven by demographic trends.
For investors and fund managers, Ambeas diversified service offerings and strategic focus on quality and compliance position it as a stable investment in the growing healthcare landscape. Its emphasis
Additional Sources for AMBEA Stock
AMBEA Stock Overview
Market Cap in USD | 884m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception |
AMBEA Stock Ratings
Growth Rating | 59.9 |
Fundamental | 76.0 |
Dividend Rating | 53.1 |
Rel. Strength | 80.5 |
Analysts | - |
Fair Price Momentum | 122.13 SEK |
Fair Price DCF | 510.58 SEK |
AMBEA Dividends
Dividend Yield 12m | 1.49% |
Yield on Cost 5y | 3.57% |
Annual Growth 5y | 6.87% |
Payout Consistency | 75.0% |
AMBEA Growth Ratios
Growth Correlation 3m | 61.3% |
Growth Correlation 12m | 95.8% |
Growth Correlation 5y | 23.2% |
CAGR 5y | 21.23% |
CAGR/Max DD 5y | 0.37 |
Sharpe Ratio 12m | 1.42 |
Alpha | 73.28 |
Beta | 0.818 |
Volatility | 35.55% |
Current Volume | 74.7k |
Average Volume 20d | 222.9k |
As of April 19, 2025, the stock is trading at SEK 110.40 with a total of 74,697 shares traded.
Over the past week, the price has changed by +6.15%, over one month by -0.72%, over three months by +17.38% and over the past year by +79.55%.
Yes, based on ValueRay Fundamental Analyses, Ambea (ST:AMBEA) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 75.95 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMBEA as of April 2025 is 122.13. This means that AMBEA is currently undervalued and has a potential upside of +10.63% (Margin of Safety).
Ambea has no consensus analysts rating.
According to ValueRays Forecast Model, AMBEA Ambea will be worth about 133.2 in April 2026. The stock is currently trading at 110.40. This means that the stock has a potential upside of +20.63%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 129.3 | 17.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 133.2 | 20.6% |